Polymorphism Pro64His within galectin-3 has functional consequences at proteome level in thyroid cells

Introduction The single nucleotide polymorphism (SNP) rs4644 at codon 64 of galectin-3 (gal-3, gene name: LGALS3), specifying the variant proline (P64) to histidine (H64), is known to affect the protein’s functions and has been associated with the risk of several types of cancer, including differentiated thyroid carcinoma (DTC). Materials and methods To deepen our understanding of the biological effects of this SNP, we analyzed the proteome of two isogenic cell lines (NC-P64 vs. NA-H64) derived from the immortalized non-malignant thyrocyte cell line Nthy-Ori, generated through the CRISPR-Cas9 technique to differ by rs4644 genotype. We compared the proteome of these cells to detect differentially expressed proteins and studied their proteome in relation to their transcriptome. Results Firstly, we found, consistently with previous studies, that gal-3-H64 could be detected as a monomer, homodimer, and heterodimer composed of one cleaved and one uncleaved monomer, whereas gal-3-P64 could be found only as a monomer or uncleaved homodimer. Moreover, results indicate that rs4644 influences the expression of several proteins, predominantly upregulated in NA-H64 cells. Overall, the differential protein expression could be attributed to the altered mRNA expression, suggesting that rs4644 shapes the function of gal-3 as a transcriptional co-regulator. However, this SNP also appeared to affect post-transcriptional regulatory mechanisms for proteins whose expression was oppositely regulated compared to mRNA expression. It is conceivable that the rs4644-dependent activities of gal-3 could be ascribed to the different modalities of self-dimerization. Conclusion Our study provided further evidence that rs4644 could affect the gal-3 functions through several routes, which could be at the base of differential susceptibility to diseases, as reported in case-control association studies.

[1]  L. Poliseno,et al.  Strategies for single base gene editing in an immortalized human cell line by CRISPR/Cas9 technology , 2024, 3 Biotech.

[2]  M. Taheri,et al.  A review on the role of NDRG1 in different cancers , 2023, Molecular Biology Reports.

[3]  Gary D Bader,et al.  The reactome pathway knowledgebase 2022 , 2021, Nucleic Acids Res..

[4]  E. A. Phelps,et al.  Physical tuning of galectin-3 signaling , 2021, Proceedings of the National Academy of Sciences.

[5]  L. Poliseno,et al.  Pro64His (rs4644) polymorphism within galectin-3 is a risk factor of differentiated thyroid carcinoma and affects the transcriptome of thyrocytes engineered via CRISPR/Cas9 system. , 2020, Thyroid : official journal of the American Thyroid Association.

[6]  Gautier Koscielny,et al.  Open Targets Genetics: systematic identification of trait-associated genes using large-scale genetics and functional genomics , 2020, Nucleic Acids Res..

[7]  Zhaoxia Wang,et al.  Heterogeneous nuclear ribonucleoprotein (hnRNPL) in cancer. , 2020, Clinica chimica acta; international journal of clinical chemistry.

[8]  L. Pieroni,et al.  Putative Biomarkers for Malignant Pleural Mesothelioma Suggested by Proteomic Analysis of Cell Secretome , 2020, Cancer Genomics & Proteomics.

[9]  Jie-rong Huang,et al.  Liquid-liquid phase separation and extracellular multivalent interactions in the tale of galectin-3 , 2020, Nature Communications.

[10]  R. Maddala,et al.  Calponin-3 deficiency augments contractile activity, plasticity, fibrogenic response and Yap/Taz transcriptional activation in lens epithelial cells and explants , 2020, Scientific Reports.

[11]  S. Wiseman,et al.  Beyond immunohistochemistry and immunocytochemistry: a current perspective on galectin-3 and thyroid cancer , 2019, Expert review of anticancer therapy.

[12]  W. Liang,et al.  Galectin-3 may serve as a marker for poor prognosis in colorectal cancer: A meta-analysis. , 2019, Pathology, research and practice.

[13]  Alka A. Potdar,et al.  hnRNP L-mediated RNA switches function as a hypoxia-induced translational regulon. , 2019, Biochemical and biophysical research communications.

[14]  Stephen Burgess,et al.  PhenoScanner V2: an expanded tool for searching human genotype–phenotype associations , 2019, Bioinform..

[15]  P. Donnelly,et al.  The UK Biobank resource with deep phenotyping and genomic data , 2018, Nature.

[16]  A. Urbani,et al.  A Proteomic Approach to Uncover Neuroprotective Mechanisms of Oleocanthal against Oxidative Stress , 2018, International journal of molecular sciences.

[17]  V. Hogan,et al.  Galectin-3 and cancer stemness , 2018, Glycobiology.

[18]  L. Lavra,et al.  Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z , 2018, International journal of molecular sciences.

[19]  Jun Yan,et al.  Galectin-3 rs4652 A>C polymorphism is associated with the risk of gastric carcinoma and P-glycoprotein expression level. , 2017, Oncology letters.

[20]  Yu-Hao Lin,et al.  The intrinsically disordered N-terminal domain of galectin-3 dynamically mediates multisite self-association of the protein through fuzzy interactions , 2017, The Journal of Biological Chemistry.

[21]  Ming Li,et al.  Correlations of Galectin-3 Gene Polymorphisms with Risk and Prognosis of Cervical Cancer in Chinese Populations: A Case-Control Study , 2017, Oncology Research and Treatment.

[22]  Kyong-Tai Kim,et al.  Heterogeneous nuclear ribonucleoprotein (hnRNP) L promotes DNA damage-induced cell apoptosis by enhancing the translation of p53 , 2017, Oncotarget.

[23]  E. Leteurtre,et al.  Galectin-3 is a non-classic RNA binding protein that stabilizes the mucin MUC4 mRNA in the cytoplasm of cancer cells , 2017, Scientific Reports.

[24]  J. Jin,et al.  Calponin isoforms CNN1, CNN2 and CNN3: Regulators for actin cytoskeleton functions in smooth muscle and non-muscle cells. , 2016, Gene.

[25]  E. Sağlam,et al.  LGALS3 and AXIN1 gene variants playing role in the Wnt/β-catenin signaling pathway are associated with mucinous component and tumor size in colorectal cancer , 2016, Bosnian journal of basic medical sciences.

[26]  M. Bugliani,et al.  Glucagon-like peptide 1 protects INS-1E mitochondria against palmitate-mediated beta-cell dysfunction: a proteomic study. , 2015, Molecular bioSystems.

[27]  M. Sun,et al.  Galectin-3 in cancer. , 2014, Clinica chimica acta; international journal of clinical chemistry.

[28]  Andreas Krämer,et al.  Causal analysis approaches in Ingenuity Pathway Analysis , 2013, Bioinform..

[29]  F. Ciregia,et al.  A multidisciplinary approach to study a couple of monozygotic twins discordant for the chronic fatigue syndrome: a focus on potential salivary biomarkers , 2013, Journal of Translational Medicine.

[30]  Y. Wada,et al.  Rock-dependent calponin 3 phosphorylation regulates myoblast fusion. , 2013, Experimental cell research.

[31]  H. Westra,et al.  A Genome-Wide Association Study of Circulating Galectin-3 , 2012, PloS one.

[32]  Huamin Wang,et al.  Overexpressed Galectin-3 in Pancreatic Cancer Induces Cell Proliferation and Invasion by Binding Ras and Activating Ras Signaling , 2012, PloS one.

[33]  R. Bresalier,et al.  A galectin‐3 sequence polymorphism confers TRAIL sensitivity to human breast cancer cells , 2011, Cancer.

[34]  B. Caillou,et al.  Wnt/β-Catenin Signaling Pathway Is a Direct Enhancer of Thyroid Transcription Factor-1 in Human Papillary Thyroid Carcinoma Cells , 2011, PloS one.

[35]  V. Hogan,et al.  Cleavage of galectin‐3 by matrix metalloproteases induces angiogenesis in breast cancer , 2010, International journal of cancer.

[36]  J. Köhrle,et al.  Proteomic approach reveals novel targets for retinoic acid-mediated therapy of thyroid carcinoma , 2010, Molecular and Cellular Endocrinology.

[37]  Y. Kloog,et al.  Galectin-3 Promotes Chronic Activation of K-Ras and Differentiation Block in Malignant Thyroid Carcinomas , 2010, Molecular Cancer Therapeutics.

[38]  F. Couch,et al.  Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study. , 2008, Cancer research.

[39]  A. Pinchera,et al.  Fine-needle aspiration of thyroid nodules: proteomic analysis to identify cancer biomarkers. , 2008, Journal of proteome research.

[40]  B. Haugen,et al.  Discovery and validation of protein abundance differences between follicular thyroid neoplasms. , 2008, Cancer research.

[41]  V. Hogan,et al.  Galectin-3 cleavage: a novel surrogate marker for matrix metalloproteinase activity in growing breast cancers. , 2007, Cancer research.

[42]  Mirna Flögel,et al.  Galectin-3: an open-ended story. , 2006, Biochimica et biophysica acta.

[43]  V. Castronovo,et al.  Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3 , 2004, Oncogene.

[44]  Y. Kloog,et al.  Galectin-3 Augments K-Ras Activation and Triggers a Ras Signal That Attenuates ERK but Not Phosphoinositide 3-Kinase Activity* , 2004, Journal of Biological Chemistry.

[45]  Yoshifumi Yamamoto,et al.  Malignant transformation of thyroid follicular cells by galectin-3. , 2003, Cancer letters.

[46]  A. Scaloni,et al.  Nuclear localization of Galectin-3 in transformed thyroid cells: a role in transcriptional regulation. , 2003, Biochemical and biophysical research communications.

[47]  L. Liotta,et al.  Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. , 1994, Biochemistry.

[48]  M. Mattéi,et al.  Thyroid nuclear factor 1 (TTF‐1) contains a homeodomain and displays a novel DNA binding specificity. , 1990, The EMBO journal.

[49]  T. Dörk,et al.  Apoptosis gene polymorphisms and risk of prostate cancer: a hospital-based study of German patients treated with brachytherapy. , 2013, Urologic oncology.